Bora Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 11, 2021 at 04:05 pm EDT
Share
Bora Pharmaceuticals Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 1,194.049 million compared to TWD 362.109 million a year ago. Operating income was TWD 193.090 million compared to TWD 58.309 million a year ago. Net income was TWD 137.500 million compared to TWD 43.368 million a year ago. Basic earnings per share from continuing operations was TWD 2.54 compared to TWD 0.8 a year ago. Diluted earnings per share from continuing operations was TWD 2.51 compared to TWD 0.8 a year ago. For the half year, sales was TWD 2,561.105 million compared to TWD 734.712 million a year ago. Operating income was TWD 642.888 million compared to TWD 103.014 million a year ago. Net income was TWD 471.940 million compared to TWD 87.837 million a year ago. Basic earnings per share from continuing operations was TWD 8.72 compared to TWD 1.65 a year ago. Diluted earnings per share from continuing operations was TWD 8.62 compared to TWD 1.64 a year ago.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
